Suppression of puberty with long-acting goserelin (Zoladex-LA): Effect on gonadotrophin response to GnRH in the first treatment cycle

Clinical Endocrinology

Volumn 57, Issue 2, 2002, Pages 223-230

  Trueman, Julie A ^a   Tillmann, Vallo ^b   Cusick, Colin F ^b   Foster, Peter ^a   Patel, Leena ^a   Hall, Catherine M ^b   Price, David A ^b   Clayton, Peter E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; GOSERELIN; ZOLADEX LA;

AGE; ARTICLE; BRAIN INJURY; CHILD; CLINICAL ARTICLE; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; GONADOTROPIN RELEASE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS, PITUITARY; GOSERELIN; HUMANS; INFANT; LUTEINIZING HORMONE; MALE; PITUITARY GLAND; PUBERTY, PRECOCIOUS; TESTOSTERONE; TIME FACTORS;

EID: 0036373894     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2002.01571.x     Document Type: Article

References (34)

1. Plasma gonadotropins and estrogens in girls with idiopathic precocious puberty
2. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty
3. Idiopathic central precocious puberty in girls as a model of the effect of plasma estradiol level on growth, skeletal maturation and plasma insulin-like growth factor I
4. Ovaries in sexual precocity
5. Diagnostic value of fluorometric assays in the evaluation of precocious puberty
6. A simplified gonadotrophin-releasing hormone test for precocious puberty
7. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty
8. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report
9. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty
10. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: A potential new treatment for idiopathic precocious puberty
11. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: Results of studies in prostate cancer
12. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer
13. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer
14. Three-month depot of goserelin acetate: Clinical efficacy and endocrine profile
15. Pelvic ultrasound findings in different forms of sexual precocity
16. Clinical review 14: Pathophysiology and treatment of sexual precocity
17. Advances in the treatment of precocious puberty
18. Efficacy of leuprolide therapy in children with central precocious puberty
19. Laboratory monitoring of children with precocious puberty
20. Effects of leuprolide in the treatment of central precocious puberty
21. Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious puberty
22. Variations in pattern of pubertal changes in girls
23. Variations in the pattern of pubertal changes in boys
24. Suppression of puberty with depot GnRH analogues: Lack of correlation between clinical and biochemical indices
25. Two-year results of treatment with depot leuprolide acetate for central precocious puberty
26. Gonadotropin secretory dynamics during puberty in normal girls and boys
27. Depot leuprolide acetate dosage for sexual precocity
28. Efficacy of Zoladex-LA (goserelin) in the treatment of girls with central precocious or early puberty
29. Premature thelarche and central precocious puberty: The relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone
30. Attributes of the radiographic standard of reference for the National Health Examination Survey
31. Clinical applications of LHRH and its analogues
32. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer
33. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: Effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis
34. Drug treatment in precocious puberty